A randomized phase II study with a phase I lead-in to assess the antitumor efficacy of the MEK inhibitor Trametinib alone or in combination with GSK2141795, an AKT inhibitor in patients with recurrent or persistent endometrial cancer.
Principal Investigator
Shannon Westin, MD
Status
Terminated
Date Opened To Accrual
September 30 2013
Date Closed to Accrual
July 18 2015
Date of Study Termination
April 10 2020
Disease Site
Gynecologic [GY]
Uterine Corpus
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the relative activity of trametinib (MEK inhibitor) alone or in combination with GSK2141795 (AKT inhibitor) for patients with recurrent or persistent endometrial cancer by progression-free survival.
Patient Population
Patients with recurrent or persistent endometrial cancer by progression-free survival.
Target Accrual
148
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.